Sector News

Shire anounces director and senior management changes

August 22, 2017
Life sciences

On August 21, 2017, Shire, a biotechnology company focused on developing therapies for rare diseases, announced that chief financial officer (CFO) Jeff Poulton will be leaving the company at the end of the year to serve as CFO at Indigo, a start-up company based in Boston that uses the plant microbiome to improve the productivity and sustainability of agriculture.

Poulton will continue to serve as CFO as the board conducts a formal search for his successor. During this transition period, Poulton will also remain on the company’s executive committee and board of directors, and will continue to support the company’s on-going business review.

“It has been a privilege to work for Shire and to have played a part in the exceptional growth story of such an inspirational company. It has been a difficult decision, but in departing Shire, I wanted to join a smaller organization where I can play a role in building a new company,” said Poulton, in a company press release. “As Shire finalizes the integration of Baxalta and focuses on paying down debt, this also presents a perfect time for me to begin this transition. I know I leave Shire well positioned to pursue its strategy and deliver value for shareholders, supported by a strong Finance team.”

Effective immediately, the company also announced Joanne Cordeiro as their new chief human resources officer and member of the executive committee. She takes over the role previously held by Ginger Gregory. Cordeiro joined Shire in March 2011 and has been serving as interim head of human resources since March 2017.

Source: Shire

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).